Medical Science Liaison and Field Medical Activities
What this domain tests
Field medical is where compliance risk is highest and where the exam tests role boundaries most heavily: scientific exchange with experts, insight capture, trial site support, and the prohibitions that define the role.
Core rules
- The MSL's currency is scientific exchange with external experts: disease state, data, guidelines, safety, and the evidence gaps relevant to the product's lifecycle.
- Prohibited: product promotion, proactive discussion of unapproved uses, distribution of samples or promotional items, negotiating prices or reimbursement, and any compensation tied to sales.
- Insights gathered from the field are anonymised, aggregated and shared with medical, clinical and HEOR partners. They inform strategy; they are not a route to influence promotional messaging.
- Trial support includes site identification and feasibility input, investigator engagement, and helping sites understand protocol requirements - without disclosing confidential sponsor data to commercial colleagues.
- Every interaction is documented in the CRM promptly: attendees, topics, materials provided, and any adverse event or product complaint, which is escalated to pharmacovigilance.
Worked example
An investigator tells an MSL that enrolment is lagging because the eligibility criteria exclude a common comorbidity. The correct action is to capture the insight, document it, and route it to clinical operations and medical leadership for consideration - not to promise a protocol amendment, and not to share the site's enrolment data with the sales team, which has no need to know.
Traps that cost marks
- Assuming MSLs may attend sales meetings to "add credibility".
- Measuring MSL performance on prescribing or sales outcomes.
- Discussing unapproved data proactively rather than only in response to a genuine scientific question.